What Артогистан Treats: Main Uses and Benefits

This injectable medication is commonly used to help with symptoms related to physical discomfort during conditions characterized by periods of heightened symptoms, specifically distressing, generalized itching (pruritus) and the sudden, widespread appearance of hives (urticaria). It is considered relevant for managing these acute skin manifestations. It provides support that helps ease the overall symptom burden and assists with maintaining functional stability when skin symptoms become disruptive.

It is applied in clinical settings that involve acute or unstable symptom patterns—including swelling associated with acute or disruptive episodes (angioedema)—and for managing symptom clusters that interfere with daily functioning such as severe sneezing, profuse runny nose, and tearing. The medication may assist with supportive relief during temporary symptom imbalance and supports the patient during difficult episodes by contributing to eased distress. This treatment is used in situations involving certain distressing symptoms when additional symptomatic support is needed.

---

Quick Fact: Relief for Acute Allergic Symptoms

Property	Description
Target Symptoms	Distressing itching, hives, swelling associated with acute changes, profuse nasal discharge
Use Context	Clinical settings with acute or unstable symptom patterns
Core Benefit	Supportive relief during temporary symptom imbalance
Relevant Conditions	Urticaria, Angioedema, Severe Allergic Rhinitis

---

The eligibility for Clemastine Fumarate injection is strictly defined by regulatory authorities based on patient population, age, and pre-existing conditions.

Populations with Prohibited Use (Contraindications)

Use is strictly prohibited for patients with a known hypersensitivity to Clemastine or similar antihistamines, and for patients currently taking Monoamine Oxidase Inhibitors (MAOIs). The medicine is also contraindicated in neonates, premature infants, and nursing mothers. Further prohibitions apply to conditions sensitive to anticholinergic effects, including narrow-angle glaucoma and pyloroduodenal obstruction. Use is also not recommended for treating acute asthma attacks.

Age and Condition-Based Restrictions

While use is generally established for adults and adolescents (typically 12 years), safety and efficacy have not been established in children under 12 years in some regions. Older adults (60 years) are subject to considerable caution due to increased susceptibility to effects like sedation. For pregnancy, use is restricted to situations only if clearly needed (Pregnancy Category B). Use requires caution in patients with hepatic or renal impairment.

This official regulatory classification, established in governmental labeling, provides clear limits on the population eligible for the medicine and is the definitive basis for all use decisions.

Interactions with other medicines and products

Official regulatory information for Clemastine Fumarate (Артогистан) details specific drug–drug and drug–substance interaction patterns, primarily revolving around additive pharmacodynamic effects.

Contraindicated Combinations and Exposure Outcome

Co-administration with Monoamine Oxidase (MAO) Inhibitors is strictly contraindicated according to official prescribing information. This restriction is based on the documented outcome that MAO inhibitors can prolong and intensify the anticholinergic effects of the antihistamine.

Pharmacodynamic Reinforcement

Combining this injection with Central Nervous System (CNS) Depressants results in additive CNS depression. This official product class interaction includes substances such as barbiturates, hypnotics, sedatives, and tranquilizers. The drug–substance interaction with alcohol is also documented to cause this same additive CNS depressant effect.

Other Interaction Considerations

Official labeling does not specify mandatory time-based separation rules for co-administration. However, regulatory documents note a population-specific consideration: elderly patients (approximately 60 years or older) are more susceptible to experiencing increased dizziness, sedation, and hypotension when the antihistamine is combined with CNS depressants. No specific interactions involving CYP enzymes or drug transporters are explicitly documented in the official prescribing information.

How Артогистан Works: Mechanism of Action

---

Antagonism of Peripheral Histamine Signaling

The drug's core mechanism is competitive antagonism at peripheral Histamine H1 receptors, primarily found on endothelial and smooth muscle cells. This molecular action directly prevents the binding of endogenous histamine, thereby modulating the signal transduction cascade initiated by histamine and resulting in the maintenance of microvascular integrity and decreased vasodilation.

---

Central and Autonomic System Modulation

Beyond peripheral effects, the molecule readily engages central H1 receptors within the brain's alertness pathways, resulting in modulation of system activity. Concurrently, the molecule possesses secondary antagonism at muscarinic acetylcholine receptors, which influences the autonomic control of glandular secretions. The central H1 antagonism produces physiological effects on pathways regulating alertness and a decreased rate of glandular secretion.

---

Boundaries of Mechanism Specificity

The mechanism is defined by its high specificity for histamine-mediated processes. This means the drug's effect profile is inherently constrained to conditions where histamine is the dominant signaling molecule. The mechanism does not modulate physiological effects driven by other, non-histamine inflammatory mediators, defining the functional boundary of the drug’s biological activity.

How Артогистан is Used

Артогистан is a solution for injection containing Clemastine Fumarate. This medication is exclusively administered through a parenteral route, meaning it is given via intramuscular (IM) or intravenous (IV) injection, typically in a clinical setting for acute symptom management.

---

Official Administration Guidelines

Administration Aspect	Details
Approved Routes	Intramuscular (IM) and Intravenous (IV) injection
Frequency Pattern	As-needed for acute intervention, with doses potentially repeated
Context of Use	Acute, short-term management; not intended for continuous chronic use

Standard Dosing Regimens

Dosing recommendations may vary slightly by region; the following regimens are based on standard international prescribing information.

• Adult Standard Single Dose: 2 mg of clemastine.
• Maximum Adult Daily Dose: The total dose administered must not exceed 6 mg over a 24-hour period.

Specific Use Instructions

1. Intravenous (IV) Preparation: For IV administration, the solution must be diluted with an appropriate solution, such as 5% glucose or isotonic saline, before use.

2. IV Administration Speed: The diluted IV injection must be administered slowly, taking approximately 2 to 3 minutes to complete the injection.

3. Population Adjustments: Dosing requires modification in specific groups. For children, the dose is calculated based on body weight, at 0.025 mg/kg per day, with a maximum single dose of 2 mg. Furthermore, lower doses are recommended for older adults (over 60 years of age).

Research evidence / Overview of studies for Артогистан

---

Evidence for Use in Acute Allergic Symptoms

Артогистан, which contains Clemastine Fumarate, was studied for its use as an injectable treatment in conditions characterized by acute or disruptive episodes, specifically severe hives (urticaria) and significant swelling (angioedema). The foundational research includes short-term Clinical Trials and Comparative Studies that explored the use of this injection in situations requiring rapid pharmacological activity. Researchers monitored patient-reported outcomes describing perceived discomfort and outcomes describing episodic or acute changes in skin manifestations.

The early trials and subsequent regulatory reviews described patterns of pharmacological activity observed soon after administration, aligning with the research focus on rapid symptom change. Studies reported measurements of how fast symptoms like itching and swelling changed in the observed populations during the first 24 hours after the injection. This evidence contributes to understanding symptom patterns in conditions linked to inflammatory or irritative states.

How the Injection Compares to Placebo and Other Treatments

Research has explored the performance of this medication in comparison to an inactive substance (placebo) and, in some cases, other medicines used for acute allergy relief. These Comparative Studies are relevant in evidence describing how symptoms are measured when assessing short-term or episodic symptom patterns.

The research examined whether there were measurable differences in changes to symptom scores and in the need for additional interventions between the treatment groups. Results often highlight changes measured over defined time intervals, but these findings describe group patterns, not personal outcomes.

Long-Term Data and Follow-Up in Clinical Research

Because the injectable form of Артогистан was studied for acute and immediate use, the follow-up periods in the primary trials were typically Short-term. Research was studied for only short-term symptom changes and studies monitored patient responses primarily within the first day.

Long-term effects are not fully established. There is limited information for long-term outcomes regarding the use of this injection. The evidence provides context but not individual predictions.

Evidence in Special Populations

The main body of research for the injectable form was evaluated in Adults and Adolescents (age 12 and above) who were experiencing acute allergic events. These groups constitute the primary study populations for which research describes the short-term use.

Data for certain groups remain insufficient. For example, follow-up durations were limited across all studied groups, and evidence is limited for individuals with complex medical histories. The results apply only to the populations studied.

Key Limitations and Uncertainty in the Evidence Base

The evidence base, while established, presents certain Research Limitation Frames. For instance, contemporary comparative evidence is lacking between this first-generation injection and newer forms of allergy medication. Sample sizes were modest in some of the foundational studies, which is common for older drugs.

Data for certain groups remain insufficient. Evidence quality varies across studies. These limitations describe data gaps regarding symptom patterns over extended periods.

Key Studies & References WHO ATC Classification Index: Clemastine (R06AA04)

Common questions about Артогистан (FAQ)

---

Q: Is Artogistan used only for osteoarthritis?

According to official regulatory documents, Artogistan (Clemastine) is indicated for the relief of acute allergic symptoms, such as severe hives or angioedema. It is not approved or intended for the treatment of osteoarthritis or other degenerative joint diseases.

---

Q: Does Artogistan help with back or lower back pain?

The therapeutic indications for Artogistan are strictly limited to the management of allergic conditions that require rapid intervention. Its official labeling does not include the use of the drug to relieve non-allergic pain in the back or lower back.

---

Q: Does Artogistan actually speed up bone fusion in fractures?

Artogistan (Clemastine) is an antihistamine. Its mechanism of action and official indications are focused on counteracting allergic reactions and do not involve speeding up bone healing or fracture repair.

---

Q: How long does the effect last after the Artogistan course is finished?

Clinical pharmacology studies indicate that the antihistamine effect of Clemastine (Artogistan) typically lasts between 10 to 12 hours, and in some cases, up to 24 hours after a single dose. The duration of effect is based on observations from single-dose studies and can vary among individuals.

---

Q: Can Artogistan be taken if there are kidney or liver problems?

Official regulatory documents advise caution when using Artogistan in patients who have pre-existing issues with liver or kidney function. This is because the medication is metabolized in the liver and eliminated primarily by the kidneys. A healthcare professional must assess its appropriateness, particularly when kidney or liver function is compromised.

---

Q: Does Artogistan affect blood pressure?

Among the documented serious adverse reactions of Clemastine (Artogistan) are hypotension (low blood pressure) and tachycardia (rapid heartbeat). Regulatory documents state that caution is required for use in patients with pre-existing cardiovascular conditions.

---

Q: Is Artogistan suitable for treating gonarthrosis (knee joint osteoarthritis)?

Artogistan is indicated for treating acute allergic events. It is not intended for the treatment of gonarthrosis (knee joint osteoarthritis) or other chronic musculoskeletal conditions.

---

Q: Is Artogistan prescribed in courses, or can it be taken continuously?

The injectable form of Artogistan is specifically intended for short-term, acute intervention as needed. It is not meant for continuous or chronic long-term use, according to regulatory guidelines.

---

Q: Does it mean that Artogistan stimulates cartilage tissue regeneration?

Artogistan (Clemastine) is scientifically classified as a first-generation antihistamine. Its mechanism is focused on blocking histamine receptors, and it is not officially linked to stimulating the regeneration or repair of cartilage tissue.

---

Q: Is a doctor's prescription needed to buy Artogistan?

Yes, the injectable form of Clemastine (Artogistan) is generally classified as a prescription-only medicine (Rx Only). It is typically administered in a clinical setting for acute care.

---

Q: Do I need to follow a special diet while being treated with Artogistan?

Official product information does not mandate any specific dietary requirements while undergoing treatment with Clemastine. However, co-administration with alcohol is specifically addressed in regulatory documents, which indicate that the combination should be avoided due to the risk of increased CNS depression (drowsiness and sedation).

---

Q: From what age is Artogistan permitted?

Artogistan is strictly contraindicated in neonates, premature infants, and nursing mothers. While it is primarily used in adults and adolescents (typically 12 years and older), the appropriate dose for children in the 6–12 year age range should be determined by a healthcare provider.

---

Q: Can I play sports during the course of treatment with Artogistan?

Regulatory information advises caution and states that activities requiring mental alertness, such as operating machinery or driving, may need to be avoided until the individual's response to the medicine is known, due to the risk of drowsiness and dizziness.

---

Q: Does Artogistan help with cervical osteochondrosis?

Artogistan is indicated only for the treatment of acute allergic conditions. It does not have official indications or approval for the treatment of cervical osteochondrosis or related pain syndromes.

---

Q: Does Artogistan affect the composition of blood?

Official safety labeling documents rare but serious adverse reactions affecting the hematopoietic system (blood formation). These serious effects include blood disorders such as agranulocytosis and aplastic anemia.

---

Q: Can Artogistan be used for joint pain caused by injury?

The drug is indicated for the treatment of acute allergic states. Its official purpose is not the relief of joint pain or inflammation that is caused by physical trauma or injury.

---

Q: What excipients are included in the Artogistan solution?

In addition to the active substance, Clemastine Fumarate, the solution for injection may contain excipients (inactive ingredients) commonly used in parenteral preparations, such as sorbitol, ethanol, and water for injection, as stated in the product description.

---

Q: Is Artogistan a chondroprotector or a painkiller?

Artogistan (Clemastine) is officially classified as a first-generation antihistamine. It does not belong to the class of chondroprotectors and is not primarily used for pain relief.

The official regulatory requirements dictate specific conditions for storing and disposing of Артогистан (Clemastine Fumarate Solution for Injection) to ensure product integrity and safety.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Do not store above 25 C and do not freeze the solution.
Protection	Store in the original package to protect it from light.
Child Safety	Keep the medicine out of the sight and reach of children.
In-Use Stability	The solution must be used immediately after opening the ampoule.

Disposal Instructions

Any unused, expired, or waste material must be handled according to strict pharmaceutical waste protocols. Disposal must be conducted in accordance with local regulations and not through household waste or wastewater systems. These measures prevent the unintended release of the medicine into the environment.